SrasV1, Ncbi, Merge, bibRecord, 001516

Anti-RNA virus activity of polyoxometalates.

Identifieur interne : 001516 ( Ncbi/Merge ); précédent : 001515; suivant : 001517

Anti-RNA virus activity of polyoxometalates.

Auteurs : Shiro Shigeta [Japon] ; Shuichi Mori ; Toshihiro Yamase ; Norio Yamamoto ; Naoki Yamamoto

Source :

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [ 0753-3322 ] ; 2006.

RBID : pubmed:16737794

Descripteurs français

KwdFr :
- Animaux, Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Composés du tungstène (pharmacologie), Composés du tungstène (usage thérapeutique), Composés du vanadium (usage thérapeutique), Coronavirus (), Grippe humaine (traitement médicamenteux), Humains, Maladies virales (traitement médicamenteux), Orthomyxoviridae (), Ribavirine (pharmacologie), Ribavirine (usage thérapeutique), Résistance virale aux médicaments, Synergie des médicaments, Titane (usage thérapeutique), Virus à ARN ().
MESH :
- pharmacologie : Antiviraux, Composés du tungstène, Ribavirine.
- traitement médicamenteux : Grippe humaine, Maladies virales.
- usage thérapeutique : Antiviraux, Composés du tungstène, Composés du vanadium, Ribavirine, Titane.
- Animaux, Coronavirus, Humains, Orthomyxoviridae, Résistance virale aux médicaments, Synergie des médicaments, Virus à ARN.

English descriptors

KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Coronavirus (drug effects), Drug Resistance, Viral, Drug Synergism, Humans, Influenza, Human (drug therapy), Orthomyxoviridae (drug effects), RNA Viruses (drug effects), Ribavirin (pharmacology), Ribavirin (therapeutic use), Titanium (therapeutic use), Tungsten Compounds (pharmacology), Tungsten Compounds (therapeutic use), Vanadium Compounds (therapeutic use), Virus Diseases (drug therapy).
MESH :
- chemical , pharmacology : Antiviral Agents, Ribavirin, Tungsten Compounds.
- chemical , therapeutic use : Antiviral Agents, Ribavirin, Titanium, Tungsten Compounds, Vanadium Compounds.
- drug effects : Coronavirus, Orthomyxoviridae, RNA Viruses.
- drug therapy : Influenza, Human, Virus Diseases.
- Animals, Drug Resistance, Viral, Drug Synergism, Humans.

Abstract

The anti-RNA virus activity of polyoxometalates (POM) is reviewed, with a special emphasis on the anti-respiratory virus activities. There are many causative agents of acute viral respiratory infections; and it is rather difficult to identify the relevant agent in a given case by rapid clinical means. During acute progress of infection before the definitive diagnosis is obtained physicians need to prescribe certain broad spectrum anti-viral drugs. A titanium containing polyoxotungstate, PM-523 exhibited potent anti-influenza virus (FluV) A and anti-respiratory syncytial virus (RSV) activities in vitro. Therapeutic effect of FluV A infected mice with aerosol inhalation of PM-523 was proven. A vanadium substituted polyoxotungstate, PM-1001 has antiviral activity against FluV A, RSV, parainfluenza virus (PfluV) type 2, Dengue fiver virus, HIV-1 and SARS coronavirus in vitro. Thus, POMs have been proven to be broad spectrum and non-toxic anti-RNA virus agents in both in vitro and in vivo experiments and are promising candidates for first-line therapeutics in acute respiratory diseases.

DOI: 10.1016/j.biopha.2006.03.009
PubMed: 16737794

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002221
to stream PubMed, to step Curation: 002221
to stream PubMed, to step Checkpoint: 002297

Links to Exploration step

pubmed:16737794

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-RNA virus activity of polyoxometalates.</title>
<author><name sortKey="Shigeta, Shiro" sort="Shigeta, Shiro" uniqKey="Shigeta S" first="Shiro" last="Shigeta">Shiro Shigeta</name>
<affiliation wicri:level="1"><nlm:affiliation>Bureau of Prefectural Hospitals, Fukushima Prefecture, Japan. sshigeta@fmu.ac.jp</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Bureau of Prefectural Hospitals, Fukushima Prefecture</wicri:regionArea>
<wicri:noRegion>Fukushima Prefecture</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mori, Shuichi" sort="Mori, Shuichi" uniqKey="Mori S" first="Shuichi" last="Mori">Shuichi Mori</name>
</author>
<author><name sortKey="Yamase, Toshihiro" sort="Yamase, Toshihiro" uniqKey="Yamase T" first="Toshihiro" last="Yamase">Toshihiro Yamase</name>
</author>
<author><name sortKey="Yamamoto, Norio" sort="Yamamoto, Norio" uniqKey="Yamamoto N" first="Norio" last="Yamamoto">Norio Yamamoto</name>
</author>
<author><name sortKey="Yamamoto, Naoki" sort="Yamamoto, Naoki" uniqKey="Yamamoto N" first="Naoki" last="Yamamoto">Naoki Yamamoto</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16737794</idno>
<idno type="pmid">16737794</idno>
<idno type="doi">10.1016/j.biopha.2006.03.009</idno>
<idno type="wicri:Area/PubMed/Corpus">002221</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002221</idno>
<idno type="wicri:Area/PubMed/Curation">002221</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002221</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002297</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002297</idno>
<idno type="wicri:Area/Ncbi/Merge">001516</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Anti-RNA virus activity of polyoxometalates.</title>
<author><name sortKey="Shigeta, Shiro" sort="Shigeta, Shiro" uniqKey="Shigeta S" first="Shiro" last="Shigeta">Shiro Shigeta</name>
<affiliation wicri:level="1"><nlm:affiliation>Bureau of Prefectural Hospitals, Fukushima Prefecture, Japan. sshigeta@fmu.ac.jp</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Bureau of Prefectural Hospitals, Fukushima Prefecture</wicri:regionArea>
<wicri:noRegion>Fukushima Prefecture</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mori, Shuichi" sort="Mori, Shuichi" uniqKey="Mori S" first="Shuichi" last="Mori">Shuichi Mori</name>
</author>
<author><name sortKey="Yamase, Toshihiro" sort="Yamase, Toshihiro" uniqKey="Yamase T" first="Toshihiro" last="Yamase">Toshihiro Yamase</name>
</author>
<author><name sortKey="Yamamoto, Norio" sort="Yamamoto, Norio" uniqKey="Yamamoto N" first="Norio" last="Yamamoto">Norio Yamamoto</name>
</author>
<author><name sortKey="Yamamoto, Naoki" sort="Yamamoto, Naoki" uniqKey="Yamamoto N" first="Naoki" last="Yamamoto">Naoki Yamamoto</name>
</author>
</analytic>
<series><title level="j">Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie</title>
<idno type="ISSN">0753-3322</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Coronavirus (drug effects)</term>
<term>Drug Resistance, Viral</term>
<term>Drug Synergism</term>
<term>Humans</term>
<term>Influenza, Human (drug therapy)</term>
<term>Orthomyxoviridae (drug effects)</term>
<term>RNA Viruses (drug effects)</term>
<term>Ribavirin (pharmacology)</term>
<term>Ribavirin (therapeutic use)</term>
<term>Titanium (therapeutic use)</term>
<term>Tungsten Compounds (pharmacology)</term>
<term>Tungsten Compounds (therapeutic use)</term>
<term>Vanadium Compounds (therapeutic use)</term>
<term>Virus Diseases (drug therapy)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Composés du tungstène (pharmacologie)</term>
<term>Composés du tungstène (usage thérapeutique)</term>
<term>Composés du vanadium (usage thérapeutique)</term>
<term>Coronavirus ()</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Humains</term>
<term>Maladies virales (traitement médicamenteux)</term>
<term>Orthomyxoviridae ()</term>
<term>Ribavirine (pharmacologie)</term>
<term>Ribavirine (usage thérapeutique)</term>
<term>Résistance virale aux médicaments</term>
<term>Synergie des médicaments</term>
<term>Titane (usage thérapeutique)</term>
<term>Virus à ARN ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Ribavirin</term>
<term>Tungsten Compounds</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Ribavirin</term>
<term>Titanium</term>
<term>Tungsten Compounds</term>
<term>Vanadium Compounds</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term>
<term>Orthomyxoviridae</term>
<term>RNA Viruses</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term>
<term>Virus Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Composés du tungstène</term>
<term>Ribavirine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term>
<term>Maladies virales</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Composés du tungstène</term>
<term>Composés du vanadium</term>
<term>Ribavirine</term>
<term>Titane</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Drug Resistance, Viral</term>
<term>Drug Synergism</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Coronavirus</term>
<term>Humains</term>
<term>Orthomyxoviridae</term>
<term>Résistance virale aux médicaments</term>
<term>Synergie des médicaments</term>
<term>Virus à ARN</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The anti-RNA virus activity of polyoxometalates (POM) is reviewed, with a special emphasis on the anti-respiratory virus activities. There are many causative agents of acute viral respiratory infections; and it is rather difficult to identify the relevant agent in a given case by rapid clinical means. During acute progress of infection before the definitive diagnosis is obtained physicians need to prescribe certain broad spectrum anti-viral drugs. A titanium containing polyoxotungstate, PM-523 exhibited potent anti-influenza virus (FluV) A and anti-respiratory syncytial virus (RSV) activities in vitro. Therapeutic effect of FluV A infected mice with aerosol inhalation of PM-523 was proven. A vanadium substituted polyoxotungstate, PM-1001 has antiviral activity against FluV A, RSV, parainfluenza virus (PfluV) type 2, Dengue fiver virus, HIV-1 and SARS coronavirus in vitro. Thus, POMs have been proven to be broad spectrum and non-toxic anti-RNA virus agents in both in vitro and in vivo experiments and are promising candidates for first-line therapeutics in acute respiratory diseases.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16737794</PMID>
<DateCompleted><Year>2006</Year>
<Month>12</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>04</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0753-3322</ISSN>
<JournalIssue CitedMedium="Print"><Volume>60</Volume>
<Issue>5</Issue>
<PubDate><Year>2006</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie</Title>
<ISOAbbreviation>Biomed. Pharmacother.</ISOAbbreviation>
</Journal>
<ArticleTitle>Anti-RNA virus activity of polyoxometalates.</ArticleTitle>
<Pagination><MedlinePgn>211-9</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The anti-RNA virus activity of polyoxometalates (POM) is reviewed, with a special emphasis on the anti-respiratory virus activities. There are many causative agents of acute viral respiratory infections; and it is rather difficult to identify the relevant agent in a given case by rapid clinical means. During acute progress of infection before the definitive diagnosis is obtained physicians need to prescribe certain broad spectrum anti-viral drugs. A titanium containing polyoxotungstate, PM-523 exhibited potent anti-influenza virus (FluV) A and anti-respiratory syncytial virus (RSV) activities in vitro. Therapeutic effect of FluV A infected mice with aerosol inhalation of PM-523 was proven. A vanadium substituted polyoxotungstate, PM-1001 has antiviral activity against FluV A, RSV, parainfluenza virus (PfluV) type 2, Dengue fiver virus, HIV-1 and SARS coronavirus in vitro. Thus, POMs have been proven to be broad spectrum and non-toxic anti-RNA virus agents in both in vitro and in vivo experiments and are promising candidates for first-line therapeutics in acute respiratory diseases.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shigeta</LastName>
<ForeName>Shiro</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Bureau of Prefectural Hospitals, Fukushima Prefecture, Japan. sshigeta@fmu.ac.jp</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mori</LastName>
<ForeName>Shuichi</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yamase</LastName>
<ForeName>Toshihiro</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yamamoto</LastName>
<ForeName>Norio</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yamamoto</LastName>
<ForeName>Naoki</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2006</Year>
<Month>05</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>France</Country>
<MedlineTA>Biomed Pharmacother</MedlineTA>
<NlmUniqueID>8213295</NlmUniqueID>
<ISSNLinking>0753-3322</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017973">Tungsten Compounds</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017968">Vanadium Compounds</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C102296">polyoxometalate I</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>49717AWG6K</RegistryNumber>
<NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>D1JT611TNE</RegistryNumber>
<NameOfSubstance UI="D014025">Titanium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009975" MajorTopicYN="N">Orthomyxoviridae</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012328" MajorTopicYN="N">RNA Viruses</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014025" MajorTopicYN="N">Titanium</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017973" MajorTopicYN="N">Tungsten Compounds</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017968" MajorTopicYN="N">Vanadium Compounds</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year>
<Month>02</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2006</Year>
<Month>03</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>6</Month>
<Day>2</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>12</Month>
<Day>9</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>6</Month>
<Day>2</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16737794</ArticleId>
<ArticleId IdType="pii">S0753-3322(06)00064-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.biopha.2006.03.009</ArticleId>
<ArticleId IdType="pmc">PMC7118841</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Antiviral Res. 2003 May;58(3):265-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12767474</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antivir Chem Chemother. 2001;12 Suppl 1:179-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11594684</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 1997 Mar;34(1):27-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9107383</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antivir Chem Chemother. 2000 Nov;11(6):367-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11227994</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 1997 Jul;41(7):1423-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9210659</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antivir Chem Chemother. 2005;16(1):23-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15739619</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Chem. 2000 Mar 9;43(5):778-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10715146</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Tohoku J Exp Med. 1995 Dec;177(4):315-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8928191</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Japon</li>
</country>
</list>
<tree><noCountry><name sortKey="Mori, Shuichi" sort="Mori, Shuichi" uniqKey="Mori S" first="Shuichi" last="Mori">Shuichi Mori</name>
<name sortKey="Yamamoto, Naoki" sort="Yamamoto, Naoki" uniqKey="Yamamoto N" first="Naoki" last="Yamamoto">Naoki Yamamoto</name>
<name sortKey="Yamamoto, Norio" sort="Yamamoto, Norio" uniqKey="Yamamoto N" first="Norio" last="Yamamoto">Norio Yamamoto</name>
<name sortKey="Yamase, Toshihiro" sort="Yamase, Toshihiro" uniqKey="Yamase T" first="Toshihiro" last="Yamase">Toshihiro Yamase</name>
</noCountry>
<country name="Japon"><noRegion><name sortKey="Shigeta, Shiro" sort="Shigeta, Shiro" uniqKey="Shigeta S" first="Shiro" last="Shigeta">Shiro Shigeta</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001516 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001516 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:16737794
   |texte=   Anti-RNA virus activity of polyoxometalates.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:16737794" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Anti-RNA virus activity of polyoxometalates.

Anti-RNA virus activity of polyoxometalates.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki